Mangalam Alloys operates an integrated stainless steel and alloy manufacturing facility in Gujarat, producing ingots, bars, and fasteners for industrial customers in India and international markets.
The company operates in a highly cyclical and fragmented commodity steel industry with low net margins (2.3%) and modest returns on capital (11%). While they claim a 'unique integrated' model, the financials do not show the pricing power or cost advantages typical of a structural moat.
Capital is primarily recycled into working capital and modest capacity maintenance. The company recently raised equity via an IPO to fund expansion, but high debt levels (D/E 1.87) and low interest coverage (1.7) suggest aggressive financial leverage for a commodity business.
The collapse was driven by the lethal combination of high financial leverage and a commodity downturn. As interest rates remained firm, the company's razor-thin interest coverage of 1.7 evaporated, leaving no room for error. The sudden resignation of the auditor proved to be a harbinger of deeper internal control failures, as the clerical errors in filings masked a deteriorating working capital cycle. Forced to service massive debt with a 2.3% net margin, the business eventually succumbed to a liquidity crunch, leading to significant equity dilution and a permanent loss of capital for shareholders.
RichFakir rates Mangalam Alloys Ltd's business quality as poor — 23/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Mangalam Alloys Ltd is trading about 53% below our estimate of fair value; we rate its price cheap. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Mangalam Alloys Ltd is: Not rated. A poor business at a cheap price — it does not make our shortlist right now.
RichFakir's educational estimate of Mangalam Alloys Ltd's fair value is about ₹67 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →